Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

PURPOSE: Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the safety of prolonged therapy has not been adequately studied. Here, we describe safety results of extended denosumab therapy in patients with bone metastases from the open-label extension phase of two p...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Support Care Cancer
Auteurs principaux: Stopeck, Alison T., Fizazi, Karim, Body, Jean-Jacques, Brown, Janet E., Carducci, Michael, Diel, Ingo, Fujiwara, Yasuhiro, Martín, Miguel, Paterson, Alexander, Tonkin, Katia, Shore, Neal, Sieber, Paul, Kueppers, Frank, Karsh, Lawrence, Yardley, Denise, Wang, Huei, Maniar, Tapan, Arellano, Jorge, Braun, Ada
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2015
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4669370/
https://ncbi.nlm.nih.gov/pubmed/26335402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-015-2904-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires